Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER)

Autor: J. Albanell, M.T. Martínez, M. Ramos, M. O'Connor, L. de la Cruz-Merino, A. Santaballa, N. Martínez-Jañez, F. Moreno, I. Fernández, J. Alarcón, J.A. Virizuela, J. de la Haba-Rodríguez, P. Sánchez-Rovira, L. González-Cortijo, M. Margelí, A. Sánchez-Muñoz, A. Antón, M. Casas, S. Bezares, F. Rojo

Publikováno v: European Journal of Cancer
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
European journal of cancer (Oxford, England : 1990)
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe

BACKGROUND: The potential benefit of adding palbociclib to fulvestrant as first-line treatment in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative endocrine-sensitive advanced breast cancer (ABC) patients remai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bfb87db10775362118ea1e131f46cae
http://hdl.handle.net/10230/53806

208TiP SOLTI-1303 PATRICIA: Cohort C. Combination of palbociclib with trastuzumab and endocrine therapy (ET) versus treatment of physician’s choice (TPC) in pretreated HER2-positive and hormone receptor-positive (HER2+/HR+) / PAM50 luminal metastatic breast cancer (BC): A randomized phase II trial

Autor: E.M. Ciruelos, J. Ponce, S. Pernas Simon, J. Cortés, B. Cantos, E. Garate, E. Vega Alonso, M. Mele Olive, E. Martinez De Dueñas, A. Montaño Perianez, N. Martinez, A. Perello Martorell, B. Bermejo De Las Heras, C. Arqueros Nunez, I. Fernández, J. De la Haba Rodriguez, M. Oliveira, X. González, P. Villagrasa Gonzalez, A. Prat

Publikováno v: Annals of Oncology. 33:S222-S223

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6ad4deede9a7d073fe3a34cc8e90d850
https://doi.org/10.1016/j.annonc.2022.03.227

Abstract P2-07-05: A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced stage breast cancer treated with first-line endocrine therapy

Autor: Maura N. Dickler, Jonas Bergh, William E. Barlow, S. Loibl, M. Martin, M-Yc Polley, Rita S. Mehta, J de la Haba, Kathleen S. Tenner, Hongfang Liu, Matthew P. Goetz, J Roberston, S.R.D. Johnston

Publikováno v: Cancer Research. 79:P2-07

Purpose: Endocrine based therapy is an effective strategy to manage hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC). However, nearly all patients exhibit/develop either de novo or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7cb86c8f88d40b8ad3a936d8a76e841c
https://doi.org/10.1158/1538-7445.sabcs18-p2-07-05